ArticleBioinformatics advances2026
Enhancing feature selection for ordinal outcomes using resampling-based sparse linear discriminant analysis.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Motivation: High-dimensional biomedical datasets with ordinal outcomes-such as cancer stages or treatment responses-pose significant challenges for feature selection due to strong predictor correlations and limited sample sizes. Sparse Linear Discriminant Analysis (sLDA) is widely used for simultaneous classification and feature selection. However, concerns about model stability and reproducible feature selection persist, particularly in the presence of pronounced collinearity inherent in biomedical data. Consequently, direct application of sLDA often fails to capture a reproducible set of biologically coordinated markers, resulting in signatures that lack robustness and interpretability. Results: We propose a resampling-based ensemble sLDA framework that integrates bootstrapping and subsampling to improve the stability of feature selection. By aggregating results across multiple resampled datasets, the method identifies features based on Variable Inclusion Probability (VIP) rather than relying on coefficients from standard sLDA. Compared with standard sLDA, this ensemble strategy reduces sensitivity to data perturbation and improves the stability and reproducibility of selected feature sets. Simulation studies demonstrate that the proposed ensemble framework achieves more accurate and consistent recovery of ground-truth predictors compared with the standard (non-resampled) sLDA. Applications to kidney renal papillary cell carcinoma staging and glioma grading datasets further suggest that this framework can improve predictive performance and identify biologically interpretable and reproducible feature sets, highlighting its potential utility for reliable biomarker discovery in precision medicine. Availability and implementation: The source code used in the study is available via GitHub at https://github.com/ryan-wng/RE-sLDA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.